Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HTR7 | P34969 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29744326 | 0.86 | ALDH1A1 (0.56) | ALDH1A1HIF1AVCAM1MAPTHTT | |
| SCHEMBL3192746 | 0.86 | ALDH1A1 (0.56) | ALDH1A1HIF1AVCAM1MAPTHTT | |
| SCHEMBL4418072 | 0.86 | ABCG2 (0.54) | ALDH1A1HIF1AVCAM1MAPTLMNA | |
| SCHEMBL1663978 | 0.85 | ALDH1A1 (0.54) | ALDH1A1HTR7MAPTLMNAHTT | |
| SCHEMBL11579276 | 0.84 | ALDH1A1 (0.67) | ALDH1A1HIF1AVCAM1MAPTLMNA | |
| SCHEMBL12312144 | 0.82 | PDGFRB (0.57) | ALDH1A1HTR7MAPTLMNAHTT | |
| SCHEMBL375109 | 0.82 | MAPT (0.53) | ALDH1A1HTR7MAPTLMNAAPP | |
| SCHEMBL1241731 | 0.81 | ALDH1A1 (0.47) | ALDH1A1HIF1AVCAM1MAPTLMNA | |
| SCHEMBL6314467 | 0.81 | ALDH1A1 (0.58) | ALDH1A1HIF1AVCAM1MAPTLMNA | |
| SCHEMBL717794 | 0.81 | MAPT (0.71) | ALDH1A1HTR7MAPTLMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2020408-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | Sugen, Inc. (US) | 2009-02-04 | — | — | EP | disclosed |
| US-7189721-B2 | Bicyclic protein kinase inhibitors | SUGEN INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-7119090-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| US-7071332-B2 | Indolinone derivatives as protein kinase/phosphatase inhibitors | SUGEN, INC. (US) | 2006-07-04 | — | — | US | disclosed |
| US-6878733-B1 | Formulations for pharmaceutical agents ionizable as free acids or free bases | SUGEN, INC. (US) | 2005-04-12 | — | — | US | disclosed |
| US-20040147586-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | SUGEN, INC. | 2004-07-29 | — | — | US | disclosed |
| US-20040106630-A1 | Bicyclic protein kinase inhibitors | SUGEN, INC. | 2004-06-03 | — | — | US | disclosed |
| US-20040106618-A1 | Bicyclic protein kinase inhibitors | SUGEN, INC. | 2004-06-03 | — | — | US | disclosed |
| US-20040067531-A1 | Methods of modulating protein tyrosine kinase function with substituted indolinone compounds | SUGEN, INC. | 2004-04-08 | — | — | US | disclosed |
| US-6696463-B2 | FOR THERAPY OF CELL PROLIFERATION, DIFFERENTIATION OR GROWTH DISORDERS, CANCER | SUGEN, INC. | 2004-02-24 | — | — | US | disclosed |
| US-20020058661-A1 | Bioavailability 3-heteroarylidenyl-2-indolinones active as protein tyrosine kinase inhibitors | TANG PENG CHO (US) | 2002-05-16 | — | — | US | disclosed |
| US-6350754-B2 | ANTICARCINOGENIC AGENTS | SUGEN, INC. | 2002-02-26 | — | — | US | disclosed |
| US-20010056094-A1 | Anticarcinogenic agents | TANG PENG CHO (US) | 2001-12-27 | — | — | US | disclosed |
| WO-2001094312-A2 | INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS | SUGEN, INC. (US) | 2001-12-13 | — | — | WO | disclosed |
| US-6313158-B1 | THERAPY AND PROPHYLAXIS OF CANCER | SUGEN, INC. | 2001-11-06 | — | — | US | disclosed |
| WO-2001037820-A2 | IONIZABLE INDOLINONE DERIVATIVES AND THEIR USE AS PTK LIGANDS | SUGEN, INC. (US) | 2001-05-31 | — | — | WO | disclosed |
| EP-1066257-A2 | HETEROCYLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | Sugen, Inc. (US) | 2001-01-10 | — | — | EP | disclosed |
| WO-1999048868-A9 | HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | SUGEN INC (US) | 2000-04-20 | — | — | WO | disclosed |
| US-6051593-A | USEFUL IN THE PREVENTION AND TREATMENT OF PROTEIN TYROSINE KINASE RELATED CELLULAR DISORDERS SUCH AS CANCER | SUGEN, INC. (US) | 2000-04-18 | — | — | US | disclosed |
| WO-1999048868-A2 | HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | SUGEN, INC. (US) | 1999-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056094-A1 | Anticarcinogenic agents | GSTK1, CDC42BPG, GLS | ALDH1A1 712/4885HTR7 2502/4885HIF1A 3012/4885 |
| US-20040067531-A1 | Methods of modulating protein tyrosine kinase function with substituted indolinone compounds | ABL1, LCK, PNCK | ALDH1A1 3893/4885HTR7 1021/4885HIF1A 1920/4885 |
| US-20040106618-A1 | Bicyclic protein kinase inhibitors | MAP3K20, MAP4K3, MAP4K2 | ALDH1A1 3733/4885HTR7 3386/4885HIF1A 3403/4885 |
| US-20020058661-A1 | Bioavailability 3-heteroarylidenyl-2-indolinones active as protein tyrosine kinase inhibitors | TH, DSTYK, ERBB2 | ALDH1A1 1025/4885HTR7 550/4885HIF1A 2297/4885 |
| US-20040147586-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | PHKA1, PHKA2, PDPK1 | ALDH1A1 2164/4885HTR7 1459/4885HIF1A 2876/4885 |
| US-20040106630-A1 | Bicyclic protein kinase inhibitors | MAP3K20, MAP4K3, MAP4K2 | ALDH1A1 3733/4885HTR7 3386/4885HIF1A 3403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.